Venous Thromboembolism Taskforce Audit Program

Venous Thrombosis Clinical Trial

Official title:

Venous Thromboembolism Taskforce Audit Program

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00535171
• Other study ID #: DIREG_L_01927
• Status: Completed
• Phase: N/A
• First received: September 25, 2007
• Last updated: January 21, 2010
• Start date: June 2007

Study information

• Verified date: January 2010
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
• Study type: Observational

Clinical Trial Summary

To determine the effect of an interventional campaign run by a dedicated "VTE Nurse Educator" over a 6-month period and the effect on prophylaxis rates.

To determine the proportion of medically admitted patients with risk factors for VTE.

To assess and compare the use of venous thromboembolism (VTE) prophylaxis in hospitalized medical patients versus recommendations and current guidelines.

To determine the patient characteristics of those deemed to be at risk of VTE. To determine the proportion of patients receiving appropriate thromboprophylaxis for their risk.

To determine the type and duration (where possible) of prophylaxis used.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8764
• Est. primary completion date: August 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Hospital admission for an acute illness with an in-patient hospital stay of 3 days or more.

Exclusion Criteria:

• Patients who have undergone any type of surgery during current admission

• Patients who are admitted to a ward or department that is excluded from this study e.g psychiatric, paediatric, maternity, intensive care unit, coronary care unit.

• Prior enrollment in this protocol during current admission

• Prior enrollment in a VTE study involving pharmaceutical or mechanical treatment within last 90 days.

• Admission for suspected or diagnosed deep vein thrombosis

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Thromboembolism
• Venous Thromboembolism
• Venous Thrombosis

Locations

Country	Name	City	State
Australia	Sanofi-Aventis	MacQuarie Park

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

Australia,